Skip Navigation LinksHome > April 2012 - Volume 18 - Issue 2, Neuro-oncology > Helping Patients Make the Best Decision Regarding Duration o...
CONTINUUM: Lifelong Learning in Neurology:
doi: 10.1212/01.CON.0000413668.65668.4a
Practice Issues

Helping Patients Make the Best Decision Regarding Duration of Temozolomide Chemotherapy Treatment

Groves, Morris D. Jr MD, JD; Plummer, Ava B. MPH, JD

Collapse Box


Outcomes for patients with glioblastoma have improved with the addition of temozolomide (TMZ) chemotherapy to radiation therapy followed by adjuvant TMZ for up to 1 year. Patients often wish to continue chemotherapy after the standard 1-year course. Whether to continue or to stop TMZ is a complex and stressful decision for the patient and family, and the decision should be based on a discussion of the known risks and benefits of each choice.

© 2012 American Academy of Neurology


Article Level Metrics

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.